Alzheimer’s drug trial explores gut-brain link

With new avenues of research exploring the link between the gut and the brain, an innovative Alzheimer’s drug from China offers clues.

Produced by Email Bluesky Facebook LinkedIn Reddit Whatsapp X Download PDF Meiyu Geng (seated) and the research team at Green Valley Research Institute. Credit: Shanghai Green Valley Pharmaceutical Co., Ltd Dementia affects around 50 million people with 10 million new cases annually, more than half due to Alzheimer’s disease. While patient numbers are expected to triple by 2050, few therapeutic strategies have shown promise to date. With new studies hinting at a more complex story, Meiyu Geng, a professor of pharmacology at the Shanghai Institute of Materia Medica Chinese Academy of Sciences (

related reading

• Using Interpretability to Identify a Novel Class of Alzheimer's Biomarkersgoodfire.ai
• It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardiantheguardian.com
• AI for Alzheimer’sopenaifoundation.org
• The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsnature.com
• Contrary Research on X: "The Virtual Cell Revolution" / Xx.com
• Glial Cells Play Key Role in Alzheimer’s Developmentneurosciencenews.com
• Biomarkers for Alzheimer’s Disease in the Current State: A Narrative Review - PMCncbi.nlm.nih.gov
• Why Does Ozempic Cure All Diseases?astralcodexten.com
• Blood test boosts Alzheimer's diagnosis accuracy to 94.5%, clinical study showsmedicalxpress.com
• Frontiers | Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer’s Diseasefrontiersin.org
• FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease | FDAfda.gov
• 'Breakthrough' blood test can find dementia risk before symptoms startnypost.com